Trial Profile
A Multiple Dose Study to Evaluate Pharmacokinetics and Hepatitis C Virus RNA Following Administration of MK7009 in Hepatitis C Infected Patients.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Vaniprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 28 Sep 2014 The Endpoint assessment timeframe has changed from (0-24hrs) to (148 days) according to ClinicalTrails.gov.
- 08 Feb 2012 Actual patient number is 3 according to ClinicalTrials.gov.
- 05 May 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.